Proof of Concept Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders
Bipolar Disorder · Substance Use Disorder
Enrolment: 10 · Results not recorded
Loading the evidence…
Nutraceutical · Prenylated flavonoid glycoside from Epimedium. ChEMBL holds no mechanism-of-action record for icariin, so moa_list is empty. ChEMBL max_phase 3, natural product flag true, no approval. The liposomal sustained-release formulation is a preclinical delivery construct with no separate ChEMBL or trial entity; trials listed are for icariin or standardised Epimedium prenylflavonoid extract.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Bipolar Disorder · Substance Use Disorder
Enrolment: 10 · Results not recorded
Hepatocellular Carcinoma
Enrolment: 25 · Results not recorded
Pharmacokinetics of Icariin
Enrolment: 24 · Results not recorded
Osteoporosis · Cardiovascular Disease
Enrolment: 30 · Results not recorded
Acne · Acne Scars
Enrolment: 25 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute blunt skeletal muscle injury
Icariin liposome promoted MHCIIB, vimentin and desmin expression, reduced collagen I, lowered TNF-alpha and IL-6, reduced malondialdehyde and increased superoxide dismutase activity, indicating improved muscle repair.
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.